ACADIA Pharmaceuticals (FRA:DR6) FCF Margin % : 15.56% (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ACADIA Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2024 was €38.6 Mil. ACADIA Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was €247.9 Mil. Therefore, ACADIA Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2024 was 15.56%.

As of today, ACADIA Pharmaceuticals's current FCF Yield % is 6.58%.

The historical rank and industry rank for ACADIA Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:DR6' s FCF Margin % Range Over the Past 10 Years
Min: -203173.77 Med: -38.72 Max: 16.41
Current: 16.4

During the past 13 years, the highest FCF Margin % of ACADIA Pharmaceuticals was 16.41%. The lowest was -203173.77%. And the median was -38.72%.

FRA:DR6's FCF Margin % is ranked better than
89.22% of 1002 companies
in the Biotechnology industry
Industry Median: -121.695 vs FRA:DR6: 16.40

ACADIA Pharmaceuticals FCF Margin % Historical Data

The historical data trend for ACADIA Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals FCF Margin % Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-32.54

-26.19

-22.05

-3.21

16.41

ACADIA Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															36.96	14.13	10.34	25.26	15.56

Competitive Comparison of ACADIA Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, ACADIA Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACADIA Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's FCF Margin % falls into.

Save Embed

;

Save Embed

;

ACADIA Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ACADIA Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	150.123	/	914.696
	=	16.41 %

ACADIA Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	38.564	/	247.92
	=	15.56 %

ACADIA Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ACADIA Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ACAD:USA DR6:Germany

Address

12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website

https://www.acadia.com

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

ACADIA Pharmaceuticals Headlines

No Headlines